Exelixis Stock News

Exelixis (EXEL) initiates CONTACT-03, a global phase III pivotal study of Cabometyx (cabozantinib) in combination with Roche's Tecentriq.

If you want to know who really controls Exelixis, Inc. (NASDAQ:EXEL), then you'll have to look at the makeup of its...

Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-03, a global phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with

Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-03, a global phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination

Wall Street analysts expect that Exelixis, Inc. (NASDAQ:EXEL) will announce $231.23 million in sales for the current quarter, according to Zacks. Five analysts have provided estimates for Exelixis’

BioConsortia has hired Dr. Damian Curtis to head synthetic biology platform for next generation biopesticides, biostimulants and fertilizers.

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest

Here are two stocks that might do just that: Exelixis (NASDAQ: EXEL) and Netflix (NASDAQ: NFLX). Its revenue largely depends on just one product: Cabometyx, a tyrosine kinase inhibitor (TKI) that spe

Although stock market corrections are part of the investing cycle, no investor, tenured or not, could have been prepared for what 2020 has offered. In about a four-month time span, the stock market h

These five biotech stocks have already gone on heaters of 30% or more in 2020, and all of them still have plenty of upside to spare.

Revance reports positive results from facial skin lines trial. Exelixis starts phase 3 prostate cancer trial. Galectin starts patient enrolment in NASH phase 2/

In a report issued on June 30, Andy Hsieh from William Blair reiterated a Buy rating on Exelixis (EXEL –

Invesco Ltd. lifted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 56.7% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 936,146 shares of the